Stay updated with breaking news from Urovant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB) Article appears
Press release content from Business Wire. The AP news staff was not involved in its creation.
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth and sixth paragraphs.The updated release reads:UROVANT SCIENCES ANNOUNCES APPOINTMENT OF SEF KURSTJENS AS EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICERUrov...
Review article in a peer-reviewed journal examines studies of GEMTESA published in the past 3 years Data support GEMTESA's role as an effective treatment option for overactive bladder (OAB)
Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma